Stx2eA-C- -Stx2eB- Vaccine composition for preventing or treating porcine edema disease comprising Stx2eA-C-terminal fragment-Stx2eB5 recombinant protein as an antigen
KOMIPHARM INTERNATIONAL CO., LTD.;전북대학교산학협력단;주식회사 코미팜;INDUSTRIAL COOPERATION FOUNDATION CHONBUK NATIONAL UNIVERSITY
发明人:
허진,박정희,김원일,김소영,서병주,정창기,문자영,김원경,라오 찌리,문성철,정호경,박수연,HUR JIN,PARK JUNG HEE,KIM WON IL,KIM SO YOUNG,SEO BYOUNG JU,JEONG CHANG GI,MOON JA YOUNG,KIM WON KYOUNG,RAO ZHILI,MOON SEONG CHEOL,JUNG HO KYOUNG,PARK SU Y
申请号：
KR1020180151647
公开号：
KR1021050210000B1
申请日:
2018.11.30
申请国别(地区):
KR
年份:
2020
代理人:
摘要：
In the present invention, the Stx2eA-C-terminal fragment gene and Stx2eB gene were cloned into pTWIN1 and pET30a, respectively, to overexpress the Stx2eA-C-terminal fragment-Stx2eB pentameric recombinant protein among Stx2e toxins, one of the causes of swine edema. These vectors were transformed with E. coli BL21 (DE3) pLysS. When 5 monomers Stx2eB expressed from the Stx2eB gene are gathered to form a pentagon structure, the Stx2eB pentamer is formed, and the pentameric Stx2eB and Stx2eA-C-terminal fragments are combined to stabilize the Stx2eA-C-terminal fragment-Stx2eB-pentamer Recombinant protein is produced. The recombinant protein and Alum adjuvant thus prepared were mixed and inoculated with various concentrations into the muscles when the piglets were 5 days old and 4 weeks old as an antigen to prevent edema disease. After inoculation, a significant antibody titer was observed in the piglets of the group inoculated with 50 ug and 100 ug of Stx2eA-C-terminal fragment-Stx2eB-pentameric recombinant protein compared to the control group. Mortality due to clinical symptoms was observed, but in the group inoculated with 50 ug, a death rate of about 42% was decreased compared to the control group. Moreover, in the group inoculated with 100 ug, clinical symptoms and mortality of edema disease were not observed. In addition, in the group inoculated with Stx2eB alone and alum adjuvant, 80% of the inoculated group died. Therefore, the recombinant Stx2eA-C-terminal fragment of the present invention and the Stx2eB protein are one of the toxoid vaccines, and the toxin is maintained at the site where the toxin adheres to the cells without toxic components, and the anti-Stx2eB antibody prevents the Stx2e toxin from attaching to effective cells. Therefore, it is expected to be useful in the development of a toxinoid vaccine that can prevent swine edema.본 발명은 돼지의 부종병 원인 중 하나인 Stx2e 독소 중에서 Stx2eA-C-말단 단편-Stx2eB 오량체 재조합 단백질을 과발현 시키기 위해 Stx2eA-C-말단 단편 유전자 및 Stx2eB 유전자를 각각 pTWIN1
